The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy

OBJECTIVE Intravesical therapy (IVT), chemo and immunotherapy, has made conservative, bladder‐sparing strategies a viable option for managing patients with high grade T1 bladder cancer. However, many of these patients will have recurrence and occasionally progression, questioning delayed intervention. This study examines the patterns of use of IVT in high‐grade T1 bladder cancer and the subsequent impact on survival for patients ultimately...